Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ginkgo Bioworks Holdings, Inc. filings document an operating company focused on cell engineering, autonomous lab services, and biological R&D tools. Form 8-K reports record operating and financial results, material-event disclosures, governance matters, the completed Biosecurity divestiture, and the classification of that former business within discontinued operations.
Proxy and capital-markets filings cover board and shareholder voting matters, executive compensation, equity awards, and governance practices. The filing record also describes Ginkgo's Class A common stock listed on the NYSE under DNA, registration-statement activity, at-the-market offering arrangements, material agreements, and related capital-structure disclosures.
Ginkgo Bioworks Holdings, Inc. (DNA) reported insider equity activity by Chief Financial Officer Steven P. Coen. On August 21, 2026, 743 Restricted Stock Units vested and were converted into an equal number of Class A Common shares in two tranches of 587 and 156 RSUs. On August 24, 2026, Coen sold 330 shares of Class A Common Stock at $6.977 per share to cover tax withholding obligations related to vesting; the company states these sell-to-cover trades were not discretionary. The Rule 10b5-1 trading plan checkbox was not selected.
Ginkgo Bioworks Holdings, Inc. (DNA) reports that officer Steven P. Coen has filed a notice of proposed sale of Class A common stock under Rule 144 through Fidelity Brokerage Services LLC. The notice covers 330 shares, tied to restricted stock vesting classified as compensation, with an indicated value of $2,302.47. The notice also lists a prior sale of 752 Class A shares on July 17, 2026 for $5,943.28. A remark states the sale includes an amount necessary to cover a tax obligation from the settlement of a vested equity award distribution.
Ginkgo Bioworks Holdings, Inc. insider Austin Che filed a notice of proposed sale of 2,200 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $14,652.00 and 55,383,808 Class A shares reported outstanding as of August 17, 2026.
The shares derive from prior restricted stock vesting awards of 20 and 2,180 Class A shares that vested on October 10 and October 12, 2022, respectively. The filing also lists a sale of 2,200 Class A shares on June 10, 2026 for $17,732.00 during the past three months.
Ginkgo Bioworks Holdings, Inc. reported Q2 2026 revenue from continuing operations of $20,156 thousand, down sharply from $39,134 thousand a year earlier, mainly due to reduced program scope with a large agriculture customer and fewer projects with pharmaceutical and biotechnology clients. The company still posted a sizable operating loss, with net loss from continuing operations of $57,321 thousand for the quarter and $133,380 thousand for the first half of 2026.
On April 3, 2026, Ginkgo completed the Biosecurity Divestiture, contributing its Biosecurity business to Tower Biosecurity, Inc. (Perimeter) in exchange for equity. This generated a gain on deconsolidation of $24,507 thousand and Q2 income from discontinued operations of $10,611 thousand, partially offsetting continuing losses. Ginkgo now holds an equity method investment in Perimeter of $7,615 thousand and recorded a $4,673 thousand loss on this stake in the first half.
Liquidity remains a key focus. As of June 30, 2026, cash and cash equivalents were $84,535 thousand and marketable securities $217,628 thousand, while net cash used in operating activities totaled $90,959 thousand for the first half. The company also reduced notes receivable to zero fair value, including a senior secured note to Bolt Threads, and raised $16,489 thousand of net proceeds in the first half under its at-the-market equity program, issuing 1.8 million Class A shares.
Ginkgo Bioworks Holdings, Inc. reported second quarter 2026 revenue of $20 million, down 48% from $39 million a year earlier, reflecting program rationalization from restructuring. Net loss from continuing operations was $(57) million, versus $(53) million in the prior-year quarter, and Adjusted EBITDA was $(36) million, down from $(25) million. Cash, cash equivalents and marketable securities totaled $302 million as of June 30, 2026, and the company reaffirmed full-year 2026 cash burn guidance of ($150)-($125) million.
Strategically, Ginkgo highlighted growth in autonomous lab infrastructure. It won government-backed contracts to build cloud labs at Caltech, Northwestern, the University of Maryland and a $47 million, 97-instrument autonomous lab for EMSL at Pacific Northwest National Laboratory, while continuing to scale its Nebula facility. Its new ADME-One pharma service, positioned as 10x cheaper than WuXi, signed 17 customers in its first six weeks.
Canton Barry reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. reported that ten percent owner Barry Canton received four restricted stock unit awards on July 28, 2026, covering a total of 319,332 RSUs tied to Class A Common Stock. Two grants are held directly and two indirectly via his spouse, with portions vesting 75% on October 16, 2026 and 25% on January 21, 2027, and others vesting in equal quarterly installments over 12 quarters starting October 16, 2026.
Shetty Reshma P. reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. reported that President and Founder Reshma P. Shetty received four equity awards on July 28, 2026 in the form of restricted stock units convertible into Class A Common Stock. Directly and through her spouse, she was granted 39038, 127423, 35736 and 117135 RSUs. For awards with footnote F2, 75% vests on October 16, 2026 and 25% on January 21, 2027, while awards with footnote F3 vest in equal quarterly installments over 12 quarters starting October 16, 2026.
Kelly Jason R reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. granted Chief Executive Officer and founder Jason R. Kelly two awards of restricted stock units on July 28, 2026. One grant covers 74,258 RSUs vesting 75% on October 16, 2026 and 25% on January 21, 2027. The other grant covers 309,467 RSUs vesting in equal quarterly installments over 12 quarters starting October 16, 2026. Each RSU represents a contingent right to receive one share of Class A Common Stock.
Ginkgo Bioworks Holdings, Inc. plans to host a presentation and Q&A session reviewing its business performance for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, beginning at 4:30 p.m. ET.
The session will be webcast via Ginkgo's investor relations website, with a replay available. Shareholders may submit questions in advance via X to @Ginkgo using hashtag #GinkgoResults or by emailing investors@ginkgobioworks.com. The company highlights its websites, blog, news site, and social media channels as outlets for potentially material information.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of Ginkgo Bioworks Holdings, Inc. Class A stock. BlackRock’s reporting business units collectively beneficially own 4,122,510 shares, representing 7.7% of the Class A shares outstanding. They hold sole voting power over 4,013,128 shares and sole dispositive power over 4,122,510 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client’s interest exceeds five percent of Ginkgo Bioworks’ outstanding common shares. The position is reported by BlackRock as a parent holding company through relevant subsidiaries identified in an exhibit, and the filing is signed by Managing Director Spencer Fleming.